SCHEMBL2283091

SCHEMBL2283091

COC(=O)COc1cccc(/C=C/C(=O)c2c(OC)c3ccccc3n(C)c2=O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PADI4 Q9UM07 4/20 0.50
CYSLTR2 Q9NS75 1/20 0.45
CYSLTR1 Q9Y271 1/20 0.45
ABCG2 Q9UNQ0 3/20 0.45
KCNA3 P22001 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
BCHE P06276 2/20 0.42
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
POLB P06746 1/20 0.41
NQO1 P15559 1/20 0.40
MAOB P27338 2/20 0.40
MAOA P21397 1/20 0.40
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
CYP1A1 P04798 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2283097 1.00 PADI4 (0.50) PADI4CYSLTR2CYSLTR1ABCG2KCNA3
SCHEMBL2279341 0.92 PADI4 (0.53) PADI4CYSLTR2ABCG2KCNA3L3MBTL1
SCHEMBL2279338 0.92 PADI4 (0.53) PADI4CYSLTR2ABCG2KCNA3L3MBTL1
SCHEMBL2280086 0.90 PADI4 (0.48) PADI4CYSLTR2CYSLTR1ABCG2L3MBTL1
SCHEMBL2280088 0.90 PADI4 (0.48) PADI4CYSLTR2CYSLTR1ABCG2L3MBTL1
SCHEMBL2278736 0.80 PADI4 (0.50) PADI4CYSLTR2ABCG2NQO1NPC1
SCHEMBL12374841 0.80 NQO1 (0.45) CYSLTR2CYSLTR1ABCG2KCNA3L3MBTL1
SCHEMBL2277980 0.80 ABCG2 (0.49) CYSLTR2CYSLTR1ABCG2L3MBTL1BCHE
SCHEMBL2277984 0.80 ABCG2 (0.49) CYSLTR2CYSLTR1ABCG2L3MBTL1BCHE
SCHEMBL2278731 0.80 PADI4 (0.50) PADI4CYSLTR2ABCG2NQO1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 PADI4 3678/4885CYSLTR2 829/4885CYSLTR1 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.